OTC Markets Upgrades RLTR to Highest Designation of Providing Current Information Meeting Upcoming Amended SEC Rule15c2-11 Guidelines tennesseedaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tennesseedaily.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
NEW YORK, Aug. 3, 2021 /PRNewswire/ Pomerantz LLP announces that a class action lawsuit has been filed against Orphazyme A/S ( Orphazyme or the Company ) (NASDAQ: ORPH) and certain of its officers and directors. The class action, filed in the United States District Court for the Northern District of Illinois, Eastern Division, and docketed under 21-cv-03640, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired: (a) Orphazyme American depositary shares ( ADSs ) pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Company s initial public offering conducted on or about September 29, 2020 (the IPO or Offering ); and/or (b) Orphazyme securities between September 29, 2020 and June 18, 2021, both dates inclusive (the Class Period ). Plaintiff pursues claims against the Defendants under the Securities Act of 1933 (the Securities
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
ObsEva Announces Two Cornerstone Publications Describing Clinical Trials of Nolasiban for .
ObsEva SAAugust 4, 2021 GMT
-
s
-
Published
-
Geneva, Switzerland and Boston, MA – August 4, 2021 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced the publication of two peer-reviewed papers on nolasiban, an oxytocin receptor antagonist in development for improving live birth rates in women undergoing embryo transfer following in-vitro fertilization (IVF).
ADVERTISEMENT
Human Reproduction. The study reports the results from a meta-analysis of three randomized, placebo-controlled trials showing that nolasiban increased the likelihood of live birth following IVF. Participants were administered a single oral dose of nolasiban 900 mg (n=846) or placebo (n=864) and
Icosavax Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
August 02, 2021 16:01 ET | Source: Icosavax, Inc. Icosavax, Inc. Seattle, Washington, UNITED STATES
SEATTLE, Aug. 02, 2021 (GLOBE NEWSWIRE) Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases, today announced the closing of its initial public offering of 13,953,332 shares of common stock, which includes the exercise in full by the underwriters of their option to purchase 1,819,999 additional shares, at an initial public offering price of $15.00 per share. The aggregate gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Icosavax, were
Iridium announces partnership with Canadian Coast Guard prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.